# US 2024/0246970 A1 · Substituted hetero-bicyclocompounds as subtype selective nicotinic acetylcholine receptor inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0246970 A1
- Document ID: US20240246970A1
- Status: Published application
- Kind: A1
- Application number: 18/580,788
- Filed: 2022-07-21
- Published: 2024-07-25
- Earliest claimed: 2021-07-21
- Applicants: The Board of Trustees of the University of Illinois
- Inventors: ANDREW RILEY; MALAIKA ARGADE; LISA RUSALI; CAROLYN STRAUB; KYLE KREMILLER
- Web page: https://patentgrep.com/patent/US20240246970A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61K 31/439: the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46)
- A61K 31/444: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61K 31/4725: containing further heterocyclic rings
- A61P 25/30: for treating abuse or dependence
- C07D 225/06: condensed with one six-membered ring
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In one aspect, the disclosure relates to a scaffold for a class of small molecules that selectively inhibit the α3β4 nicotinic acetylcholine receptor (nAChR) subtype, as well as molecules constructed using the scaffold and syntheses thereof. In some aspects, the scaffold can be used as a basis for synthesizing additional molecules capable of selectively inhibiting other nAChR subtypes. In a further aspect, the disclosed small molecules can be used as molecular probes to investigate the function of different nAChR subtypes and as potential treatments for addiction and other diseases.

## Claims

### Claim 1

A compound of Formula I or a pharmaceutically acceptable salt thereof:
wherein R1 and R2 are independently selected from hydrogen, C1-C4 alkyl, C1-C4 haloalkyl, C3-C6 cycloalkyl, phenyl, and deuterated C1-C4 alkyl, or wherein R1 and R2 together are part of a cycloalkyl group;
wherein R3 is selected from NR5, S, and O;
wherein R5 is selected from hydrogen, C1-C4 alkyl, and acetyl; and
wherein R4 is selected from (1) a C1-C4 alkyl or alkenyl group substituted with a substituted or unsubstituted aryl group or (2) a substituted or unsubstituted 5 to 10-membered aryl or heteroaryl group;
provided that when R1 and R2 are methyl and R3 is NH, R4 is not

### Claim 2 (depends on 1)

The compound of claim 1, wherein R1 and R2 are independently selected from hydrogen, methyl, and ethyl.

### Claim 3 (depends on 1)

The compound of claim 1, wherein R1 and R2 are methyl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein R1 and R2 together are part of a cyclopropyl group.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R3 is NR5 and R5 is hydrogen, methyl, or ethyl.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R3 is O.

### Claim 7 (depends on 1)

The compound of claim 1, wherein R1 and R2 are methyl and R3 is NH.

### Claim 8 (depends on 1)

The compound of claim 1, wherein R4 is a phenyl group substituted with one or more of: hydroxyl, nitro, amino, halo, C1-C4 haloalkyl, C1-C4 alkoxy, or C1-C4 alkyl, C3-C6 cycloalkyl, or any combination thereof.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R4 is a quinoline group substituted with one or more of: hydroxyl, nitro, amino, halo, C1-C4 haloalkyl, C1-C4 alkoxy, or C1-C4 alkyl, C3-C6 cycloalkyl, or any combination thereof.

### Claim 10 (depends on 1)

The compound of claim 1, wherein R4 is
and wherein R6a, R6b, R6c, R6d, and R6e are independently selected from hydrogen, halogen, hydroxyl, N-acetyl, —OCF3, nitro, isopropyl, cyclopropyl, tert-butyl, dimethylamino, or any combination thereof.

### Claim 11 (depends on 1)

The compound of claim 1, wherein R4 is
and wherein R7a, R7b, R7c, R7d, R7e, and R7f are independently selected from hydrogen, halogen, hydroxyl, N-acetyl, —OCF3, nitro, isopropyl, cyclopropyl, tert-butyl, dimethylamino, or any combination thereof.

### Claim 12 (depends on 1)

The compound of claim 1, wherein R4 is

### Claim 13 (depends on 1)

The compound of claim 1, wherein the compound of Formula I is selected from
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

The compound of claim 1, wherein the compound of Formula I is selected from
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

The compound of claim 1, wherein the compound of Formula I is selected from
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

The compound of claim 1, wherein the compound is a (+) enantiomer, a (−) enantiomer, or any combination thereof.

### Claim 17 (depends on 1)

The compound of claim 1, wherein the compound of Formula I has a chiral center a
wherein the stereochemistry at chiral center a is substantially R, substantially S, or racemic.

### Claim 18 (depends on 1)

A method for inhibiting the activity of at least one nicotinic acetylcholine receptor (nAChR) subtype, the method comprising contacting the nAChR subtype with the compound of claim 1.

### Claim 19 (depends on 18)

The method of claim 18, wherein the at least one nAChR subtype is an α3β4 nAChR.

### Claim 20 (depends on 18)

The method of claim 18, wherein the compound has an IC50 for the nAChR subtype of less than about 1 μM.

### Claim 21 (depends on 18)

The method of claim 18, wherein the compound has an IC50 for the nAChR subtype of from about 0.25 to about 0.5 μM.

### Claim 22 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1, an enantiomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

### Claim 23 (depends on 1, 22)

A method for treating or preventing a disease or disorder associated with aberrant activity of at least one nicotinic acetylcholine receptor (nAChR) subtype in a subject, the method comprising administering a therapeutically effective amount of the compound of claim 1 or the composition of claim 22 to the subject.

### Claim 24 (depends on 23)

The method of claim 23, wherein the at least one nAChR subtype is an α3β4 nAChR.

### Claim 25 (depends on 23)

The method of claim 23, wherein the subject is a mammal.

### Claim 26 (depends on 25)

The method of claim 25 wherein the mammal is a human, dog, cat, rat, mouse, guinea pig, non-human primate, rabbit, or horse.

### Claim 27 (depends on 23)

The method of claim 23, where the disease or disorder comprises substance abuse, addiction, or any combination thereof.
